search
Back to results

A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients

Primary Purpose

Diabetes Mellitus, Type 1, Metabolic Disorder

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Control
Telecare system
Sponsored by
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring Telemedicine, Type 1 diabetes, Metabolic control optimisation, Health care costs, Intervention study, Access to internet

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diabetes Mellitus 1 (DM1) patients with more than 5 years of evolution with values of glycosylated haemoglobin (HbA1c) > 8% aged between 18 and 50 years.
  • Undergoing treatment with multiple doses of insulin.
  • Having 3-4 blood sugar tests per day.
  • Suitable knowledge about diabetes (test of Diabetes knowledge questionnaire (DKQ2)>25).
  • Patients with a computer and access to home internet.

Exclusion Criteria:

  • Pregnant diabetes mellitus 1 (DM1) patients.
  • History of severe hypoglycemia.
  • Manipulation of results.
  • Psychiatric disorder.
  • Incapable of carrying out intensive therapy monitoring.
  • Physical and/or visual incapacity.
  • Participating in another study.
  • Patients with infertility treatment (ISCI).

Sites / Locations

  • Hospital de Cruces
  • Hospital Clínic de Barcelona
  • Hospital Clínico de Madrid
  • Hospital Carlos Haya
  • Hospital Clínico de Valencia

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Interventional telematic

Control

Arm Description

80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.

80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).

Outcomes

Primary Outcome Measures

Optimise metabolic control
Insulin dose and criteria (timetables, habits of diet and activity). Autocontrol description and survey about perception of hypoglycaemia Knowledge about diabetes: Diabetes knowledge questionnaire (DKQ2) <25/35

Secondary Outcome Measures

Patient costs
Time, expenses and ordinary activity (studies and work) that the patient could not do in order to attend to the face-to-face visits.
Medical team costs
Time, expenses and healthcare issues used in the follow-up phase of the metabolic control.
Quality of life
Quality-of-life questionnaire designed for diabetes mellitus (EsDQOL) and standardised instrument for use as a measure of health outcome (EuroQoL).
Treatment adherence
Self-Care Inventory-revised (SCI-R), a self-report measure of perceived adherence to diabetes self-care recommendations, among adults with diabetes.

Full Information

First Posted
April 14, 2011
Last Updated
January 28, 2015
Sponsor
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
search

1. Study Identification

Unique Protocol Identification Number
NCT01337141
Brief Title
A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients
Official Title
Multicentric Intervention Study Evaluating the Efficiency of the Implementation in the Spanish Health System of a Telematic System Applied to Metabolic Control Optimization for Type 1 Diabetes Mellitus (DM1) Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A greater visit frequency between the diabetes mellitus 1 (DM1) patient and the medical team increases the possibilities to improve metabolic control. The support of telematic visits can support the patient and the health system. Patients and Method: 160 patients (from 5 participating centres) with type 1 diabetes mellitus (DM1) candidates for improved metabolic control selected according to inclusion and exclusion criteria. The telecare system used is comprised of the patient Unit and the doctor Unit. The system allows the patient to send glucose values, insulin doses, carbohydrate contribution and other events via the internet. Both the patient and the professional can use this information via the telecare system platform. Work hypothesis The application of interactive telematic systems between patient-health team will improve the cost effectiveness of care programmes for optimisation of metabolic control directed towards diabetes mellitus (DM1) patients. Objectives: General Objective Evaluate the impact of the telecare system on the efficiency of economic and clinical management of human and material resources directed to a program of metabolic control optimisation in diabetes mellitus 1 (DM1) patients as well as the level of metabolic control and the quality of life of the patients. Specific objectives To identify and analyse the influence of the telecare system on patient costs in time, money and normal work or school activity which the patient has to stop to carry out the physical visits for following the programme. To identify and analyse the influence of the telecare system on medical team costs in time, money and care organisation directed towards the monitoring phase of the metabolic control care programme. To identify and analyse the influence of the telecare system on the level of metabolic control: Glycosylated haemoglobin and the presence of acute hypoglycemic and hyperglycaemic complications in diabetes mellitus 1 (DM1) patients that follow the metabolic optimisation programme. To identify and analyse the influence of the telecare system on the quality of life of the patient measured in satisfaction scale, impact, social/work concern and concern relating to diabetes. To identify and analyse the influence of the telecare system on the adherence to different treatment components.
Detailed Description
*Title: Multicentric random, prospective, open and comparative intervention study evaluating the efficiency of the implementation in the Spanish Health System of a telematic system applied to metabolic control optimization for type 1 diabetes mellitus (DM1) patients. Protocol: 1) Pre-intervention. After the patient is informed and accepts the protocol they make 2 visits for planning individual treatment. 2) Random Assignment in 2 Groups: A) Intervention (telecare system). B) Control. The intervention group patients will be trained in the telecare system machine. Both groups will make the same number of 6 visits over 6 months: Intervention Group (5 telematics and 1 hospital), Control group (6 hospital). Results will be assessed at 3 and 6 months and reassessed at 12 months. Patients The objective of the present study is to demonstrate that telematic control of diabetes mellitus is not inferior to the face to face visit control system, while showing an added value an important reduction in costs. Cost information from three studies have been used for the calculation of the sample 2,3,20 in diabetes mellitus 1 (DM1) patients, some followed in a telematic form (210 ± 184€) and other in the form of face to face visits (376 ± 278€). Relating to this, 72 patients per group are needed to obtain a statistical power of 99% and an alpha level of 0.05 (two-sided). 80 patients per group will be needed to be randomised taking into account a 10% loss percentage. Participating Centres Hospital Clínico. Barcelona Hospital Clínico. Valencia Hospital Carlos Haya. Málaga Hospital Clínico. Madrid Hospital de Cruces. Barakaldo Each arm will include 80 patients, 160 as a total.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1, Metabolic Disorder
Keywords
Telemedicine, Type 1 diabetes, Metabolic control optimisation, Health care costs, Intervention study, Access to internet

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
154 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Interventional telematic
Arm Type
Experimental
Arm Description
80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
Arm Title
Control
Arm Type
Other
Arm Description
80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
Intervention Type
Other
Intervention Name(s)
Control
Other Intervention Name(s)
Control group do not use telematic system.
Intervention Description
7 face-to-face visits.
Intervention Type
Device
Intervention Name(s)
Telecare system
Other Intervention Name(s)
Medical Guard Diabetes®, - Access in internet: https://www.medicalguard.net/, - Pulso Ediciones SL
Intervention Description
5 telematic visits and 2 face-to-face visits.
Primary Outcome Measure Information:
Title
Optimise metabolic control
Description
Insulin dose and criteria (timetables, habits of diet and activity). Autocontrol description and survey about perception of hypoglycaemia Knowledge about diabetes: Diabetes knowledge questionnaire (DKQ2) <25/35
Time Frame
Month 12
Secondary Outcome Measure Information:
Title
Patient costs
Description
Time, expenses and ordinary activity (studies and work) that the patient could not do in order to attend to the face-to-face visits.
Time Frame
Month 6
Title
Medical team costs
Description
Time, expenses and healthcare issues used in the follow-up phase of the metabolic control.
Time Frame
Month6
Title
Quality of life
Description
Quality-of-life questionnaire designed for diabetes mellitus (EsDQOL) and standardised instrument for use as a measure of health outcome (EuroQoL).
Time Frame
Month 12
Title
Treatment adherence
Description
Self-Care Inventory-revised (SCI-R), a self-report measure of perceived adherence to diabetes self-care recommendations, among adults with diabetes.
Time Frame
Month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diabetes Mellitus 1 (DM1) patients with more than 5 years of evolution with values of glycosylated haemoglobin (HbA1c) > 8% aged between 18 and 50 years. Undergoing treatment with multiple doses of insulin. Having 3-4 blood sugar tests per day. Suitable knowledge about diabetes (test of Diabetes knowledge questionnaire (DKQ2)>25). Patients with a computer and access to home internet. Exclusion Criteria: Pregnant diabetes mellitus 1 (DM1) patients. History of severe hypoglycemia. Manipulation of results. Psychiatric disorder. Incapable of carrying out intensive therapy monitoring. Physical and/or visual incapacity. Participating in another study. Patients with infertility treatment (ISCI).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enric Esmatjes, MD and PhD
Organizational Affiliation
Hospital Clínic de Barcelona (CIBERDEM)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Cruces
City
Barakaldo
ZIP/Postal Code
48903
Country
Spain
Facility Name
Hospital Clínic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital Clínico de Madrid
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Carlos Haya
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital Clínico de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain

12. IPD Sharing Statement

Links:
URL
http://www.ciberdem.org
Description
CIBERDEM website, including a description of TELEMED-DIABETES

Learn more about this trial

A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients

We'll reach out to this number within 24 hrs